ArticleWorld journal of urology2026
Outcomes of the novel EXIME prostate stent: initial experience in a South African setting.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUrinary retention due to Benign Prostatic Hyperplasia (BPH) is a frequent and serious urological emergency. This study evaluated the efficacy and clinical outcomes of the EXIME temporary prostatic stent as an alternative to traditional catheterisation.
methodsA prospective study including 50 male patients presenting with BPH-related urinary retention or those awaiting definitive surgery was performed. The EXIME stent was inserted as an outpatient for a one-month indwelling period. Primary endpoints included voiding efficacy and ease of use. Secondary outcomes assessed sexual function restoration, pain and bacterial colonisation rates.
resultsSpontaneous voiding was achieved in all 50 patients with a median maximum flow rate (Qmax) of 17.8 ml/s [IQR 12.9-21.7] and a median post-void residual (PVR) of 20 ml [IQR 10-37]. A significant restoration of sexual activity was observed, with a resumption rate of 88% among previously sexually active men (p < 0.001). Surrogate markers for bacterial colonisation improved with dipstick nitrite positivity dropping from 26% pre-insertion to 0% at removal (p < 0.001). Procedurally, 90% of insertions were graded as extremely easy to easy (VAS 1-3) and 84% of patients reported only minimal to uncomfortable pain (VAS 1-3). The failure rate was 4% with only two early removals documented.
conclusionThis study represents the first clinical experience on this novel innovation on the continent of Africa, demonstrating a safe, effective, and well-tolerated alternative to traditional catheterization by providing immediate symptom relief and improved outcomes regarding sexual function and bacterial colonisation thus supporting its use in the management of BPH-related urinary retention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.